top of page
 
Memory Studies

Sponsor: Cognito Therapeutics, Inc.  Status:  Active and recruiting

A Randomized, Double-blind, Sham-controlled, Adaptive- Design Pivotal Study of Sensory Stimulation in Subjects With Alzheimer's Disease (Hope Study, CA-0011)

To learn more go to ClinicalTrials.gov Identifier: NCT05637801 

 

Inclusion Criteria:

  • Men and Women age 50-90

  • Alzheimer's disease diagnosis with at least 6-month decline in cognitive function

  • Non-childbearing potential (females post menopausal or males, if active with females of child bearing potential, willing to use appropriate birth control)

  • Mini-Mental State Exam (MMSE) 15-28

  • Available/consenting Study Partner

Exclusion Criteria:

  • Seizure disorder

  • Hospitalization in previous 30 days

  • Living in continuous care nursing home (assisted living permitted)

  • Inability to have an MRI or significant abnormality on MRI screening

More Criteria apply call us for more Infromation

Sponsor: Eli Lilly and Company   Status: Closed recruitment

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

ClinicalTrials.gov Identifier: NCT04437511 

Sponsor: Eli Lilly and Company   Status: Closed recruitment

A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease (Trailblazer ALZ-4

ClinicalTrials.gov Identifier :NCT05108922  

Sponsor: Biogen  Status Closed recruitment

Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (Aducanumab) in Subjects With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

Sponsor: Novo Nordisk A/S    Status: Closed Recruitment 

A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE)                                                     

To Learn more, go to ClinicalTrials.gov Identifier: NCT04777396

A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE Plus)

To Learn more, go to ClinicalTrials.gov Identifier: NCT04777409

 

I


Respiratory Studies 

Indication: COPD Chronic Obstructive Pulmonary Disease

Sponsor: Chiesi Farmaceutici S.p.A.   Status: Active and Recruiting

A Phase III, 52-week, Multinational, Multicenter, Randomized, Double-blind, 2-arm Parallel Group Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide (CHF 5993) With the Fixed Dose Dual Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate (CHF 1535), Both Administered Via pMDI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

To learn more go to ClinicalTrials.gov Identifier: NCT04320342 

Inclusion Criteria:

  • Outpatient

  • Male or female subjects aged ≥40 years

  • A female is eligible to participate in the study if she is of non-childbearing potential defined as physiologically incapable of becoming pregnant OR childbearing potential with negative serum and urine pregnancy tests at screening, and is willing to use highly effective birth control methods for the full duration of the study

  • COPD diagnosis for at least 12 months before the screening visit in accordance with the definition by the GOLD 2020 Report

  • Current or ex-smokers who quit smoking at least 6 months prior to screening with a smoking history of at least 10 pack-years [pack-years = (number of cigarettes per day x number of years)/20]

Exclusion Criteria:

  • Female subjects who are pregnant (as evident by a positive urine hCG or serum β-hCG test) or lactating

  • Requirement of long term (> 15 hours daily) oxygen therapy

More Criteria Apply, call us for more information

Indication: Alzheimer's Disease

Sponsor: Othair Prothena Limited Status: Active and recruiting

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of PRX012 in Subjects with Alzheimer’s Disease

Inclusion Criteria:

  • Subjects between 55 and 85 years, inclusive, at the time of signing the ICF

  •  Body mass index between 18.0 and 32.0 kg/m2, inclusive

  • Have suitable venous access for blood draw though phlebotomy in the upper extremities

Exclusion Criteria:

  • PRX012 excipientshypersensitivity to any of the components of the study drug (Section 5.1) including monoclonal antibodies or fusion proteins, or related compounds; or allergy or allergy, hypersensitivity, or serious adverse reactions to chimeric, human, or humanized History or presence of systemic autoimmune disorders, known severe food allergy;

  • York Heart Association Class III or IV), or clinically significant conductionHistory of unstable angina, myocardial infarction, advanced chronic heart failure (New abnormalities within 1 year before screening

More Criteria apply, call us for more information

Sponsor: Eli Lilly and Company   Status: Recruiting on hold will start soon

Assessment of Safety, Tolerability, and Efficacy Measured by Amyloid Reduction of LY3372993 in Early Symptomatic Alzheimer's Disease

To learn More, go to ClinicalTrials.gov Identifier:NCT05463731   

Inclusion Criteria:

  • Gradual and progressive change in cognitive function ≥6 months prior to screening.

  • A Mini-Mental (MMSE) score of 20 to 28 (inclusive) at screening.

  • Has a P-tau result consistent with the presence of amyloid pathology.

  • Has an amyloid PET scan result consistent with the presence of brain amyloid pathology.

  • Have a reliable study partner who will provide written informed consent to participate and is in frequent contact with the participant.

Exclusion Criteria:

  • Significant neurological disease affecting the central nervous system (CNS) other than AD, that may affect cognition or ability to complete the study.

  • Current serious or unstable illnesses that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of <24 months.

  • History of of clinically significant multiple or severe drug allergies.

  • Have any contraindications for MRI or positron emission tomography (PET). 

More Criteria apply call us for more Infromation

Sponsor: Eli Lilly and Company   Status: Closed Recruitment 

A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)                            

To learn more go to ClinicalTrials.gov Identifier: NCT05026866 

Sponsor: AstraZeneca   Status: Closed Recruitment 

A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter Variable Length Study to Assess the Efficacy and Safety of PT010 Relative to PT009 and Symbicort® in Adult and Adolescent Participants With Inadequately Controlled Asthma

To learn more, go to ClinicalTrials.gov Identifier: NCT04609904

I


Women Health Studies 

Indication: Interstitial Cystitis/Bladder Pain Syndrome

Sponsor: Purdue Pharma. L.P.  Status Will start enrolling soon

 

Multicenter, Randomized, Double-blind Placebo-controlled, Crossover Study to Investigate Effects of V117957 in Female Subjects with Interstitial Cystitis/Bladder Pain Syndrome

Inclusion Criteria:

  • Be female, age ≥18 years and capable of voiding independently. A female is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following applies: 

  • Not a woman of childbearing potential (WOCBP).

  • Female participants of childbearing potential must agree to use a reliable method of contraception with a failure rate of less than 1% per year

  • Has diagnosis of IC/BPS or meets criteria for IC/BPS as defined by the American Urology Association as “an unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms for more than six weeks duration, in the absence of infection or other identifiable causes”.

  • More Criteria Apply, please call us for more information.

Sponsor: Purdue Pharma L.P.  Status: Closed Recruitment

Multicenter, Randomized, Double-blind Placebo-controlled, Crossover Study to Investigate Effects of V117957 in Female Subjects with Overactive Bladder Syndrome

Inclusion Criteria:

  • Be female, age 18-64 years, non-pregnant, non-lactating, and capable of voiding independently.

  •  Have symptoms of OAB including urinary urgency and urinary frequency with daily incontinence for ≥3 months.

More Criteria apply, call us for more information.

Sponsor: Teva Pharmaceuticals USA Status Closed recruitment 

A Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Inserts 4 mcg (Teva Pharmaceuticals, Inc.) With IMVEXXY® (Estradiol Vaginal Inserts) (TherapeuticsMD, Inc.) in the Treatment of Dyspareunia in Women With Vulvar and Vaginal Atrophy

For more Information go to ClinicalTrials.gov Identifier: NCT05617820

I

bottom of page